{"id":"full-dose-of-doac","safety":{"commonSideEffects":[{"rate":"2-4% major bleeding annually","effect":"Bleeding (major and minor)"},{"rate":"1-2%","effect":"Gastrointestinal bleeding"},{"rate":"5-10%","effect":"Dyspepsia"},{"rate":"0.3-0.8%","effect":"Intracranial hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DOACs are a class of anticoagulants that work by directly inhibiting either Factor Xa (apixaban, rivaroxaban, edoxaban) or Factor IIa/thrombin (dabigatran), key enzymes in the coagulation cascade. By blocking these factors, DOACs prevent the formation of thrombin and subsequent fibrin clot formation, reducing thrombotic events while maintaining some residual coagulation capacity.","oneSentence":"Direct oral anticoagulants (DOACs) inhibit specific clotting factors to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:40.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Acute coronary syndrome (in combination with antiplatelet therapy)"}]},"trialDetails":[{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT05627375","phase":"PHASE3","title":"Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-08-16","conditions":"Venous Thromboembolic Disease","enrollment":1400},{"nctId":"NCT03285438","phase":"PHASE3","title":"REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2017-11-02","conditions":"Venous Thromboembolism","enrollment":2774}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Full dose of DOAC","genericName":"Full dose of DOAC","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct oral anticoagulants (DOACs) inhibit specific clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}